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Introduction
In the early 2000’s, two randomized controlled trials have
shown that non-invasive ventilation (NIV) could decrease
mortality of immunocompromised patients admitted to
ICU for acute respiratory failure (ARF) as compared to
standard oxygen therapy (O2) [1,2]. However, the benefits
of NIV in immunocompetent patients with ARF failure
are debated. High flow nasal cannula oxygen therapy
(High-Flow Oxygen) may offer an alternative in hypoxe-
mic patients. We recently found in a randomized
controlled trial including 310 patients with ARF that
High-Flow Oxygen decreased mortality as compared to
NIV [3]. Immunocompromised patients could be also
included in this study, except those with profound neutro-
penia. Therefore, we assessed the benefits of High-Flow
Oxygen or NIV in this subgroup of patients.
Objectives
To compare intubation and mortality rates in the subset of
immunocompromised patients admitted to ICU for ARF.
Methods
We performed a subgroup analysis of the FLORALI study.
This study included all patients with non-hypercapnic
(PaCO2 ≤ 45 mm Hg) ARF excluding patients with cardio-
genic pulmonary edema and those with underlying
chronic lung disease. Patients were assigned to three
groups according to treatment: High-Flow Oxygen, O2 or
NIV. The primary outcome was the intubation rate and
secondary outcome included 90-day mortality. We focused
on the subset of immunocompromised patients included
in this study, knowing that patients with profound neutro-
penia were excluded.
Results
Among the 310 patients with ARF, 82 (26%) were immu-
nocompromised including 26 patients in the High-Flow
Oxygen group, 30 in the O2 group, and 26 in the NIV
group. Intubation rates were 31%, 43% and 55% in the
High-Flow Oxygen, O2 and NIV groups, respectively
(p = 0.04). The 90-day mortality rates were 15%, 27% and
46% in the High-Flow Oxygen, O2 and NIV groups
(p = 0.046). Ventilator-free days at day 28 were 26 ± 6, 23
± 10 and 14 ± 13 days in the High-Flow Oxygen, O2 and
NIV groups, respectively (p < 0.0001).
Conclusions
In immunocompromised patients admitted to ICU for
acute hypoxemic respiratory failure, High-Flow Oxygen
was associated with lower intubation and mortality
rates, and a reduced duration of invasive mechanical
ventilation as compared to O2 or NIV.
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